ANN ARBOR, Mich., March 26, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that results from a preclinical study demonstrating the potential atheroprotective properties of ixmyelocel-T will be presented in a poster session at the Keystone Symposia on the Molecular Basis of Vascular Inflammation and Atherosclerosis in Big Sky, Montana starting Sunday, March 25, 2012. The poster is entitled “Ixmyelocel-T therapy alternatively activated macrophages potentially exert atheroprotective effects.”
